Ausria, a radioimmunoassay test to detect serum hepatitis, was launched in 1972 and marked the beginning of Abbott's immunodiagnostics business. A year later, the Abbott Diagnostics Division was ...

Abbott Laboratories, a healthcare giant with diverse divisions, is normalizing post-pandemic as its medical devices drive growth following a drop in Covid-test demand. The company reported 9% ...

DelveInsight's D-Dimer Testing Market Insights report provides the current and forecast market analysis, individual leading D ...

CNBC’s Jim Cramer on Friday evaluated the stock of Abbott Laboratories, a healthcare company that’s been weighed down by ...

Abbott’s ABT diversified ... Toxicology and Consumer Diagnostics. In rapid and point-of-care diagnostics businesses, the company is successfully expanding its test menu and is also capitalizing ...

Following the robust Q3 performance, Piper Sandler raised ABT’s price target to $133 from $131, keeping an Overweight rating ...

Welcome to Abbott's Third Quarter ... to sustain our growth into 2025. In our rapid and point-of-care diagnostics businesses, we continue to expand our test menus and capitalize on the growing ...

A Closer Look Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs.

Abbott has a diversified business, exciting growth avenues, and a strong dividend program. The company faces potential obstacles, including legal problems and stiff competition. However, that's no ...

Abbott didn't miss a beat in his first Sheffield Shield match since February last year, upstaging returning Test quick Mitchell Starc with four wickets to lead a NSW fightback on the opening day ...